Literature DB >> 21593513

The natural history of treated Parkinson's disease in an incident, community based cohort.

Jonathan R Evans1, Sarah L Mason, Caroline H Williams-Gray, Thomas Foltynie, Carol Brayne, Trevor W Robbins, Roger A Barker.   

Abstract

BACKGROUND: Our understanding of the natural history of idiopathic Parkinson's disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be identified for clinical trials. No previous studies have charted progression in unselected patients followed from the point of diagnosis.
METHODS: A representative cohort of 132 PD patients was followed from diagnosis for up to 7.9 years (mean 5.2 years). Comprehensive clinical and neuropsychological evaluations were performed every 18 months. Disease progression was evaluated using well validated clinical measures (motor progression and development of dyskinesia on the Unified PD Rating Scale and Hoehn-Yahr scale, dementia onset according to DSM-IV criteria). Multi-level linear modelling was used to chart the nature and rate of progression in parkinsonian symptoms and signs over time. The prognostic importance of baseline demogr‘aphic, clinical and genetic variables was evaluated using survival analysis.
RESULTS: Axial (gait and postural) symptoms evolve more rapidly than other motor features of PD and appear to be the best index of disease progression. Conversely, conventional outcome measures are relatively insensitive to change over time. Earlier onset of postural instability (Hoehn-Yahr stage 3) is strongly associated with increased age at disease onset and has a significant impact on quality of life.
CONCLUSIONS: Dementia risk is associated with increased age, impaired baseline semantic fluency and the MAPT H1/H1 genotype. The efficacy of disease modifying therapies may be more meaningfully assessed in terms of their effects in delaying the major milestones of PD, such as postural instability and dementia, since it is these that have the greatest impact on patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593513     DOI: 10.1136/jnnp.2011.240366

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  78 in total

1.  Arm swing as a potential new prodromal marker of Parkinson's disease.

Authors:  Anat Mirelman; Hagar Bernad-Elazari; Avner Thaler; Eytan Giladi-Yacobi; Tanya Gurevich; Mali Gana-Weisz; Rachel Saunders-Pullman; Deborah Raymond; Nancy Doan; Susan B Bressman; Karen S Marder; Roy N Alcalay; Ashwini K Rao; Daniela Berg; Kathrin Brockmann; Jan Aasly; Bjørg Johanne Waro; Eduardo Tolosa; Dolores Vilas; Claustre Pont-Sunyer; Avi Orr-Urtreger; Jeffrey M Hausdorff; Nir Giladi
Journal:  Mov Disord       Date:  2016-10       Impact factor: 10.338

2.  Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease.

Authors:  Vikas Kotagal; Roger L Albin; Martijn L T M Müller; Robert A Koeppe; Kirk A Frey; Nicolaas I Bohnen
Journal:  Neurology       Date:  2014-03-28       Impact factor: 9.910

Review 3.  A systematic review of loss of independence in Parkinson's disease.

Authors:  Angus D Macleod; J W Kerr Grieve; Carl E Counsell
Journal:  J Neurol       Date:  2015-07-15       Impact factor: 4.849

4.  Cerebral Amyloid Burden and Hoehn and Yahr Stage 3 Scoring in Parkinson Disease.

Authors:  Vikas Kotagal; Nicolaas I Bohnen; Martijn L T M Müller; Kirk A Frey; Roger L Albin
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

5.  Clinical progression in Parkinson's disease with features of REM sleep behavior disorder: A population-based longitudinal study.

Authors:  Aline Duarte Folle; Kimberly C Paul; Jeff M Bronstein; Adrienne M Keener; Beate Ritz
Journal:  Parkinsonism Relat Disord       Date:  2019-01-29       Impact factor: 4.891

6.  Course of psychiatric symptoms and global cognition in early Parkinson disease.

Authors:  Patricia de la Riva; Kara Smith; Sharon X Xie; Daniel Weintraub
Journal:  Neurology       Date:  2014-08-15       Impact factor: 9.910

7.  Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients.

Authors:  Aristide Merola; Laura Rizzi; Carlo Alberto Artusi; Maurizio Zibetti; Mario Giorgio Rizzone; Alberto Romagnolo; Andrea Bernardini; Michele Lanotte; Leonardo Lopiano
Journal:  J Neurol       Date:  2014-06-22       Impact factor: 4.849

8.  Risk thresholds of levodopa dose for dyskinesia in Chinese patients with Parkinson's disease: a pilot study.

Authors:  Genliang Liu; Huimin Chen; Dongning Su; Dongxu Wang; Meimei Zhang; Xuemei Wang; Zhan Wang; Yaqin Yang; Ying Jiang; Huizi Ma; Tao Feng
Journal:  Neurol Sci       Date:  2019-08-24       Impact factor: 3.307

9.  Advanced age, cardiovascular risk burden, and timed up and go test performance in Parkinson disease.

Authors:  Vikas Kotagal; Roger L Albin; Martijn L T M Müller; Robert A Koeppe; Stephanie Studenski; Kirk A Frey; Nicolaas I Bohnen
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-05-26       Impact factor: 6.053

Review 10.  Postural instability in patients with Parkinson's disease. Epidemiology, pathophysiology and management.

Authors:  Samuel D Kim; Natalie E Allen; Colleen G Canning; Victor S C Fung
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.